Corporate Profile
NovaBay Pharmaceuticals is a clinical stage company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections. The company’s Aganocide compounds mimic the body’s immune system, acting rapidly and effectively to defeat multi-drug resistant pathogens without causing resistance. NovaBay’s lead Aganocide compound is in Phase 2 clinical testing for treating Pink Eye, Impetigo and Catheter-Associated Urinary Tract Infection.
The company has significant corporate partnerships with Alcon, the world’s leading ophthalmology company, and Galderma S.A., a global pharmaceutical firm dedicated to dermatology. NovaBay has also retained proprietary early stage programs addressing large markets such as onychomycosis, or nail fungus, and common cold.
News and FeaturesAugust 24, 2010
NovaBay Pharmaceuticals Announces Resignation of Board Member
August 12, 2010
NovaBay Pharmaceuticals, Inc. Reports Second Quarter Financial Results
July 26, 2010
"The Pink Sheet" - NovaBay's Non-Antibiotic Anti-Infective Shows Efficacy In Impetigo Trial
July 21, 2010
Archive of Conference call Re: Impetigo Clinical Trial Results
Click Here To Listen
July 21, 2010
NovaBay Pharmaceuticals' Non-antibiotic Anti-infective Successful in Phase 2 Skin Infection Trial
July 15, 2010
NovaBay Pharmaceuticals Receives Notice of Allowance on Anti-infective NVC-612 and Related Compounds
May 25, 2010
NovaBay Pharmaceuticals Completes Enrollment in Phase 2 Impetigo Clinical Trial
May 12, 2010
NovaBay Pharmaceuticals, Inc. Reports First Quarter Financial Results
May 6, 2010
Positive Data on New Class of Anti-infectives Announced by NovaBay Pharmaceuticals at ARVO 2010
April 19, 2010
Archive of Conference call Re: CAUTI Trial Pipeline Update
Click Here To Listen
April 15, 2010
NovaBay Pharmaceuticals Reports Positive Data from Exploratory Phase 2 Trial
March 29, 2010
NovaBay Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
March 25, 2010
Catheter-Associated Urinary Tract Infection Expert, David Stickler, Interviewed
Click Here To Listen
February 09, 2010
NovaBay CEO Ron Najafi Presents at BIO CEO & Investor Conference
Click Here To Listen
February 02, 2010
"Towards a New Paradigm in Anti-Microbial Therapy", By Dr. Stephen Wilmarth, NovaBay Ophthalmic Advisor
January 05, 2010
Founding Director of UCLA's Urological Center and NovaBay SAB Member, Bernard Churchill, M.D., Interviewed
Click Here To Listen
December 22, 2010
World-Renowned Biofilm Expert and NovaBay SAB Member, William Costerton, Ph.D., Interviewed
Click Here To Listen
Click Here to Sign Up For NovaBay News
